AGP Executive Report
Last update: 11 hours agoBiotech Deal Shock: Jiangsu Hengrui and Bristol Myers Squibb just signed a global collaboration and licensing pact worth up to US$15.2 billion, covering 13 early-stage oncology, hematology and immunology programs; BMS pays US$600m upfront plus anniversary and milestone payments, with closing expected in Q3 2026. Macau Health Watch: The Health Bureau (SSM) says Macau’s mosquito ovitrap index jumped in April, pushing dengue and chikungunya risk higher as temperatures and rainfall accelerate Aedes breeding; authorities are also rolling out free mosquito repellents at government “Health Fuel Stations” and running a two-week stagnant-water cleanup push. Local Governance & Safety: Macau reported another 18 contraband smuggling attempts at the border and airport, while a separate stabbing incident left a 22-year-old under medical care. City Pulse: Galaxy Entertainment posted Q1 2026 results with net revenue up 11% year-on-year, but noted luck effects in quarterly comparisons.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
![<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>](https://cdn.sanity.io/images/0vv8moc6/pharmexec/92b02a7f6e0c466c155a40ec32a74d94a075d09b-1280x720.jpg)
